Aura Biosciences is applying nanotechnology to the fight against cancer. Its novel viral nanoparticle technology, developed in partnership with the National Cancer Institute (NCI), harnesses the potential of viral evolution and tumor targeting for the treatment of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/05/15 | $21,000,000 | Series B |
Advent Life Sciences Alexandria Real Estate Equities Chiesi Ventures Henri Termeer LI-COR Biosciences Ysios Capital | undisclosed |
| 09/29/16 | $8,000,000 | Venture | ||
| 12/21/17 | $30,000,000 | Series C |
Advent Life Sciences Alexandria Venture Investments Arix Bioscience  Chiesi Ventures Columbus Ventures Henri Termeer LI-COR Biosciences Lundbeckfonden Ventures Ysios Capital | undisclosed |
| 04/02/19 | $40,000,000 | Series D |
Medicxi | undisclosed |
| 03/22/21 | $12,000,000 | Series A |
Adage Capital Management Advent Life Sciences Arix Bioscience Chiesi Ventures Columbus Ventures Lundbeckfond Ventures Matrix Capital Management Medicxi Rock Springs Capital Surveyor Capital Velosity Capital Ysios Capital | undisclosed |
